Traumatic Brain Injury
Conditions
Brief summary
Brain edema is one of the main mechanisms of secondary brain injury and one factor in the prognosis of traumatic brain injury . The clinical study of glibenclamide in the treatment of brain edema after traumatic brain injury is designed to evaluate whether glibenclamide treatment can improve the blood NSE and S100β levels of severe traumatic brain injury , so order to explore the efficacy and adverse effects of this drug in the treatment of traumatic brain injury .
Detailed description
Traumatic brain injury has high morbidity,disability and mortality ; worldwide, more than 50 million new cases , mainly low and middle-income countries.The annual incidence of craniocerebral trauma in China is (55 - 64) / 100000 , with 770 - 890 thousand new cases,causing nearly 100000 deaths and hundreds of thousands of disabilities , which is a serious public safety problem .Injury mechanisms after traumatic brain injury include primary and secondary brain injury and have a lack of effective treatment .Brain edema is one of the main mechanisms of secondary brain injury and one factor in the prognosis of traumatic brain injury .In recent years , the Sur1-Trpm4 channel was found to play an important role in the onset of brain edema , with increased expression in traumatic brain injury , ischemic stroke , and ischemic and hypoxic encephalopathy , and the specific inhibitor glibenclamide can reduce brain edema .A clinical study of glibenclamide in the treatment of brain edema after traumatic brain injury to evaluate whether glibenclamide treatment can improve the blood NSE and S100β levels of severe traumatic brain injury , so order to explore the efficacy and adverse effects of this drug in the treatment of traumatic brain injury .
Interventions
DRUGglibenclamide
Glibenclamide was given orally or by nasal feeding
Sponsors
Beijing Tongren Hospital
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open label, result blind method
Intervention model description
Patients in the case group were treated with glibenclamide within 10 hours after onset, orally or through nasogastric tube, 1.25 mg each time, once every 8 hours, for 7 consecutive days. The control group was blank control.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Closed craniocerebral trauma; 2. The injury time on admission was less than 10 hours; 3. The GCS score was less than 9, and the GCS score was evaluated without sedation or using muscle relaxants; 4. They were 18-75 years old; 5. Authorized close relatives to sign informed consent.
Exclusion criteria
1. The damage time is uncertain; 2. Penetrating brain injury; 3. With spinal cord injury; 4. Severe and fatal injuries associated with other parts of the body; 5. Pregnant women or pregnancy test positive; 6. Lactating women had lactation needs during the study period; 7. blood suger is lower than 2.8 mmol / L; 8. Renal insufficiency, history of dialysis treatment, or serum creatinine more than 2.5 mg / dl; 9. The total bilirubin was more than 1.5 times of the upper limit; 10. INR was greater than 1.4; 11. Systolic blood pressure was less than 90 and had no response to fluid resuscitation; 12. Allergic to sulfonylureas; 13. There was a history of admission for brain injury, mental or neurological diseases within 3 years before brain injury; 14. The drug use was restricted due to emergency operation within 8 hours after brain injury; 15. There was a history of taking antiplatelet drugs, oral anticoagulants or heparin or low molecular weight heparin 72 hours before brain injury; 16. There was a history of taking sulfonylureas within 30 days before brain injury; 17. There was a history of participating in other drug trials within 30 days before brain injury; 18\. There was a history of G6PD deficiency; 19. There were clinical conditions that other researchers did not consider to meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum NSE and S100 β level | at 1st, 3rd,7th days after recruitment | change of the serum NSE and S100 β level concentrations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glasgow coma scale(GOS) score | at 30 days | Glasgow coma scale(GOS) score |
| Hospital mortality | at 30 days | Hospital mortality |
| The degree of brain edema | at 3rd,7th days after recruitment | measured by CT |
| The degree of midline displacement of brain CT | at 3rd,7th days after recruitment | The degree of midline displacement of brain CT |
| Intracranial pressure | up to 7 days | if have |
Countries
China
Contacts
Primary Contactqing lin
Outcome results
None listed